Investors Purchase Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Key Points

• Unusual options activity: Traders bought 1,002 put options on MRVI — a 1,791% increase from the typical daily volume of 53 — signaling elevated bearish bets or hedging activity.
• Analyst outlook and recent results: MRVI carries a consensus "Hold" rating with an average price target of $5.38; it posted a slight quarterly beat (EPS -$0.04 vs. -$0.07, revenue $49.87M) but remains unprofitable with negative margins and a projected -$0.24 EPS for the year while trading around $2.87 (market cap ~$738M).

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the target of some unusual options trading activity on Wednesday. Traders bought 1,002 put options on the stock. This represents an increase of 1,791% compared to the typical daily volume of 53 put options.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on MRVI shares. Wall Street Zen upgraded Maravai LifeSciences from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Wells Fargo & Company boosted their target price on Maravai LifeSciences from $4.00 to $4.50 and gave the company an "overweight" rating in a research note on Monday, December 15th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of "Hold" and an average price target of $5.38.

Maravai LifeSciences Price Performance

NASDAQ MRVI opened at $2.87 on Thursday. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85. The stock has a market capitalization of $737.79 million, a PE ratio of -3.19 and a beta of 0.43. The company has a 50 day moving average price of $3.26 and a two-hundred day moving average price of $3.33. Maravai LifeSciences has a 12-month low of $1.66 and a 12-month high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. The company had revenue of $49.87 million for the quarter, compared to analyst estimates of $49.06 million. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. As a group, equities analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Maravai LifeSciences

Several institutional investors have recently bought and sold shares of MRVI. Tejara Capital Ltd increased its holdings in shares of Maravai LifeSciences by 26.4% during the 3rd quarter. Tejara Capital Ltd now owns 2,453,441 shares of the company's stock valued at $7,041,000 after acquiring an additional 511,992 shares during the last quarter. Monaco Asset Management SAM lifted its holdings in Maravai LifeSciences by 315.0% in the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company's stock worth $10,494,000 after purchasing an additional 2,775,372 shares during the last quarter. Immersion Corp lifted its holdings in Maravai LifeSciences by 153.3% in the 2nd quarter. Immersion Corp now owns 990,000 shares of the company's stock worth $2,388,000 after purchasing an additional 599,164 shares during the last quarter. Royce & Associates LP boosted its position in Maravai LifeSciences by 38.0% during the third quarter. Royce & Associates LP now owns 1,761,764 shares of the company's stock worth $5,056,000 after purchasing an additional 484,908 shares during the period. Finally, First Eagle Investment Management LLC bought a new stake in Maravai LifeSciences during the third quarter worth approximately $1,294,000. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.